

Attorney Docket No.: 6200.200-US

REMARKS

Having regard to Examiners final office action dated July 29, the Examiner is respectfully requested to enter amended claim 22 filed herewith. The purpose of the amendment is to correct some typographical errors applicants have noticed in claim 22, this in order to bring the set of claims in proper form in respect of the pending appeal.

In amended claim 22 the term "less" has been deleted in line 12 and in line 13 the terms "height" and "diameter" has been replaced by "diameter" respectively "height". As appears, the reason for this amendment is that claim 22 as on file defines the opposite of what was intended. As correctly defined in present claim 21 "the diameter of the cylindrical member and the cover is substantially larger than the height of the cylindrical member and cover, respectively". This relationship is also readily apparent from fig. 1. Thus amended claim 22 now defines the correct relationship between the height and the diameter of the claimed invention.

Claim 22 presently on file also comprises some words misspelled with capital letter. This is corrected in amended claim 22.


No further amendments have been made by the applicants.

Attorney Docket No.: 6200.200-US

The Commissioner is hereby authorized to charge any fees, including fees for extensions of time, in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. Should the Examiner have any questions or concerns, he should feel free to contact the applicants' attorney to discuss them.

Date: December 14, 2004

Respectfully submitted,



Marc A. Began, Reg. No. 48,829
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

**Use the following customer number for all correspondence
regarding this application**

**23650
PATENT TRADEMARK OFFICE**